We've just published our news article with information from this morning's oral presentation session. Here's the link:
https://myelomabeacon.org/news/2012/06/04/asco-2012-multiple-myeloma-update-day-four-immunotherapy-for-myeloma/
As expected, there was continued good news about elotuzumab in combination with Revlimid and dexamethasone. This will be an important drug for myeloma patients in the next few years, as it already is being tested in Phase 3 trials -- the last phase of clinical trial testing before companies file applications with the FDA to have a drug approved for general use.
There also was promising news about a drug that hasn't gotten a lot of attention until recently: daratumumab. It is still in the early stages of testing as a potential myeloma treatment. But the first clinical trial results, which were presented at today's session, look promising. (A copy of the daratumumab presentation has been made available to the Beacon's readers; you can view it here: http://bit.ly/M0Z4S5 .)
The results for siltuximab, in combination with Velcade, were not as promising as had been hoped. There were mixed signs as to whether or not it adds efficacy to Velcade on its own. Still, the company developing siltuximab -- Johnson & Johnson -- continues to carry out and plan additional trials testing the drug as a potential new myeloma treatment.
We're now working on a summary of the poster presentations that were made available this afternoon. There were a lot of them, so it may take until tomorrow until we wrap up and publish the daily update covering those presentations.
Forums
Re: ASCO 2012 - Updates From The Meeting
Dr. Orlowski has provided The Beacon with a copy of his siltuximab presentation from yesterday. It can be viewed here: http://bit.ly/LuCJNM .
Re: ASCO 2012 - Updates From The Meeting
Another ASCO 2012 presentation has come in that we can make available to our readers. It is from Dr. Rodon and discusses trial results for the Velcade-Treanda-dexamethasone combination in relapsed/refractory patients. Here is a link to the presentation: http://bit.ly/L880oX .
Re: ASCO 2012 - Updates From The Meeting
Thanks for all the ASCO updates! They've been very interesting and helpful.
-
TerryH
Re: ASCO 2012 - Updates From The Meeting
Dr. Rajkumar has provided his presentation on induction therapy that he gave during the education session to The Beacon and permitted us to make it available to our readers. It can be viewed here (PDF): http://bit.ly/MnxAd2.
Re: ASCO 2012 - Updates From The Meeting
Thanks for the presentation notes from Dr. Rajkumar. On the graph 'implications of dex dosing', there are two type of dex, RD and Rd. Which one is the higher dose? It seems that it makes quite a difference, about 10%, for the results between the differing doses.
-
Nancy Shamanna - Name: Nancy Shamanna
- Who do you know with myeloma?: Self and others too
- When were you/they diagnosed?: July 2009
26 posts
• Page 3 of 3 • 1, 2, 3